BioTime, USCN sign option, distribution agreements
February 2012

ALAMEDA, Calif.óBioTime Inc. has announced agreements with USCN Life Science Inc. (USCN) that grant BioTime an option to license USCN's antibody-producing cell lines and certain related technology that BioTime and its subsidiary OncoCyte Corp. can use for the large-scale manufacture of the antibody components of PanC-Dx. A novel diagnostic technology, PanC-Dx was discovered at BioTime and OncoCyte and is intended to detect the presence of various cancers, including breast, colon, lung, stomach, uterine and bladder cancers. BioTime and USCN also signed a distribution agreement that grants BioTime and its subsidiaries the right to market more than 4,000 diverse ELISA and CLIA kits for detecting a wide array of proteins for the stem cell research market, which BioTime intends to sell through its subsidiary LifeMap Sciences Inc. in 2012.  

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.